| locally advanced NSCLC - (neo)adjuvant (NA) | |
| locally advanced NSCLC - (neo)adjuvant (NA) | |
| immune chekpoint inhibitors | |
| anti-PD-(L)1 | |
| nivolumab based treatment | |
| nivolumab plus SoC | CheckMate 816 |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-